B. Riley analyst William Wood raised the firm’s price target on LifeMD to $12 from $11 and keeps a Buy rating on the shares. LifeMD delivered an “impressive” top-line beat in Q4 and weight management subscribers are already up to 35,000 in Q1, placing new subscribers at 13,000, up from 8,000 and 12,000 in Q3 and Q4, respectively, highlighting weight care access demand, the analyst tells investors in a research note. The firm remains bullish on LifeMD given expected strong telehealth growth and new product offerings throughout 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LFMD:
- LifeMD Reports Fourth Quarter 2023 Results
- Lifemd, Inc. (LFMD) Q4 Earnings Cheat Sheet
- Medifast price target lowered to $40 from $67 at DA Davidson
- LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
